- In November 2023, Abbott Laboratories received FDA clearance for its i-STAT TBI plasma test, which includes advanced cardiac marker detection capabilities. This expands the use of portable point-of-care devices for rapid cardiac and neurological diagnostics in both hospital and field environments
- In June 2024, Siemens Healthineers expanded its cardiac testing portfolio by introducing the NT-proBNPII (PBNPII) assay on the Atellica Solution platform. This development aims to provide enhanced diagnostic capabilities for heart conditions
- In March 2024, Polymedco obtained 510(k) clearance by the FDA for its speedy troponin assay as a unit of its Pathfast Biomarker Analyser. This FDA-approved biomarker identifies the existence of cardiac troponin I, a critical indicator for myocardial infarction
- In October 2023, Mindray, a global provider of medical devices and solutions, launched two new cardiac biomarkers worldwide: high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions enhance Mindray's diverse portfolio for diagnosing and managing cardiovascular diseases
